🌎 30+ NEW AI-picked share strategies for exciting international marketsUnlock Global AI Picks

Vericel's preliminary Q4 revenue falls short of analyst expectations; shares fall 11% post market

Published 14/01/2025, 21:20
© Reuters.

© Reuters.

VCEL
4.83%

Investing.com -- Vericel (NASDAQ:VCEL) Corporation shares fell 11% after market close as the company reported preliminary total revenue for the fourth quarter that did not meet the average analyst estimate.

The biopharmaceutical company's preliminary total revenue fell between $75.2 million and $75.7 million, falling short of the estimated $77.9 million, according to the Bloomberg Consensus.

The company's MACI (matrix-induced autologous chondrocyte implant) net revenue was within the range of $68.2 million to $68.7 million, slightly surpassing the estimate of $68.1 million.

However, the preliminary Epicel (cultured epidermal autografts) net revenue was about $6 million, which was lower than the estimated $8.38 million. The preliminary NexoBrid revenue was about $1 million, under the estimated $1.47 million.

For the year ahead, Vericel predicts an adjusted Ebitda margin of 25% to 26%. The company also expects a gross margin in the range of 73% to 74%, which is slightly higher than the estimated 72.4%.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

Should you invest $2,000 in VCEL right now?

With VCEL making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed VCEL alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including VCEL, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is VCEL poised for similar growth? Don't miss the opportunity to find out.

Reveal Undervalued Stocks Now

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.